<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2008</study_start_year><condition>Metastatic adenocarcinoma of colon or rectum</condition><condition>Metastatic colorectal cancer</condition><disease>Metastatic Colorectal Cancer</disease><disease>Metastatic Adenocarcinoma Of Colon Or Rectum</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2524137</full_dataset_link><location>Italy</location><study_start_month>6</study_start_month><keyword>UFT</keyword><keyword>Calcium levofolinate</keyword><keyword>ELOXATIN</keyword><keyword>ERBITUX</keyword><repository>ECRIN MDR</repository><study_status>Terminated</study_status></additional><is_claimable>false</is_claimable><name>First Line UFT, OXALIPLATIN and ERBITUX combination (TEGAFOX-E) in Elderly (≥ 70 years) metastatic colorectal patients: a Phase II ITMO study.</name><description>Primary objectives: To assess the respons rate ORR (CR+PR)</description><dates><creation>2008-06-15</creation></dates><accession>2524137</accession><cross_references><EU Clinical Trials Register>2008-001355-21</EU Clinical Trials Register></cross_references></HashMap>